REGENXBIO Inc. Stock News

ROCKVILLE, Md. , April 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m.

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD.

Regenxbio (RGNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ROCKVILLE, Md., March 9, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Barclays Global Healthcare Conference Date: Thursday, March 17, 2022 Location: Loews Miami Beach Hotel, Miami, FL Presentation:…

ROCKVILLE, Md., March 9, 2022 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Barclays Global Healthcare Conference

Clinical-stage biotech, Regenxbio <> is trading sharply higher on Wednesday to record the biggest intraday gain since September after the company unveiled a new initiative…

Shares of Regenxbio (RGNX) are up 8% in after-hours trading despite the companys Q4 2021 earnings results that beat on both the top and bottom lines.

REGENXBIO's (RGNX) CEO Ken Mills on Q4 2021 Results - Earnings Call Transcript

Regenxbio press release (RGNX): Q4 GAAP EPS of $6.67 beats by $2.93.Revenue of $398.65M (+1758.5% Y/Y) beats by $142.89M.

ROCKVILLE, Md., March 1, 2022 /PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible to receive up to $1.38 billion in additional development, regulatory and commercial milestones…

Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (NASDAQ:RGNX) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is $4.31 (+447.6% Y/Y) and the consensus…

ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral presentations on Clearside''s SCS injection platform featuring the SCS Microinjector ® were given at the Bascom Palmer Eye Institute''s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022. Clearside''s presentation, entitled, "The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians" described the preclinical and clinical data demonstrating the methodology and benefits of suprachoroidal delivery. The preclinical data in multiple animal models showed the potential advantages of SCS delivery over intravitreal delivery, the durability potential of small molecule suspensions, and the possible suitability of suprachoroidal delivery for gene therapy. In conjunction with partners, Clearside''s technology is currently being explored in five clinical trials in four indications: neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, uveitic macular edema, and choroidal melanoma. "Suprachoroidal delivery via our SCS Microinjector offers clinicians several potential core benefits for treatment of their patients with back of the eye diseases: targeting of therapy to affected tissues; compartmentalization of therapy to avoid non-diseased tissues; higher bioavailability; and potential longer durability," said Thomas A.

Regenxbio Inc (NASDAQ: RGNX ) announced additional interim data from Cohorts 1-3 of Phase 1/2 trial of RGX-121 for patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), The data were shared at the 18th Annual WORLDSymposium. RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. RGX-121 is reported to be well-tolerated … Full story available on Benzinga.com